SAN
DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it
will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m.
ET.
On the call, Dr. Helen
Torley, President and Chief Executive Officer, and
Nicole LaBrosse, Chief Financial
Officer, will provide preliminary unaudited full year 2024 results
and updated 2025 and multi-year financial guidance.
Pre-registration of the live call can be accessed
via link here: https://registrations.events/direct/Q4I871904593.
The call will also be webcast live through the "Investors" section
of Halozyme's corporate website and a recording will be made
available following the close of the call. To access the webcast
and presentation materials, which will be available 15 minutes
before the call, please visit Halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing
disruptive solutions to improve patient experiences and outcomes
for emerging and established therapies. As the innovators of
ENHANZE® drug delivery technology with the proprietary enzyme
rHuPH20, Halozyme's commercially-validated solution is used to
facilitate the subcutaneous delivery of injected drugs and fluids,
with the goal of improving the patient experience with rapid
subcutaneous delivery and reduced treatment burden. Having touched
more than 800,000 patient lives in post-marketing use in nine
commercialized products across more than 100 global markets,
Halozyme has licensed its ENHANZE® technology to leading
pharmaceutical and biotechnology companies including Roche, Takeda,
Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx,
ViiV Healthcare, Chugai Pharmaceutical and Acumen
Pharmaceuticals.
Halozyme also develops, manufactures and
commercializes, for itself or with partners, drug-device
combination products using its advanced auto-injector technologies
that are designed to provide commercial or functional advantages
such as improved convenience, reliability and tolerability, and
enhanced patient comfort and adherence. The Company has two
commercial proprietary products, Hylenex® and XYOSTED®, partnered
commercial products and ongoing product development programs with
Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information
visit www.halozyme.com and connect with us on LinkedIn
and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha
Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-host-investor-conference-call-to-provide-updated-2025-financial-guidance-302342725.html
SOURCE Halozyme Therapeutics, Inc.